Mass Balance Study of [14C] ABBV-552 in Healthy Male Volunteers Following Single Oral Dose Administration
Latest Information Update: 06 May 2024
At a glance
- Drugs ABBV 552 (Primary)
- Indications Alzheimer's disease; Cognition disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
Most Recent Events
- 26 Apr 2024 Status changed from active, no longer recruiting to completed.
- 17 Apr 2024 Status changed from recruiting to active, no longer recruiting.
- 29 Feb 2024 Status changed from not yet recruiting to recruiting.